AAO: Corneal Toxicity Reported With Mirvetuximab Soravtansine
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 22, 2024 -- For patients receiving mirvetuximab soravtansine (MIRV) treatment for primary gynecologic malignancies, corneal toxicity is not uncommon, but usually resolves, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held from Oct. 18 to 21 in Chicago.
Filippos Vingopoulos, M.D., Ph.D., from Stanford University in Palo Alto, California, and colleagues examined longitudinal changes in 36 eyes of 18 patients on MIRV treatment for primary gynecologic malignancies. Corneal toxicity, visual acuity (VA), ocular therapeutic regimen, and ensuing changes in MIRV dose and spacing were recorded.
The researchers found that 47, 22, and 31 percent of the 36 eyes had moderate or severe, mild, and no corneal toxicity, respectively, at 5.5-month follow-up. Mainly after the second cycle (19 of 25), paracentral ring-like subepithelial deposits, corneal haze, and filamentous keratitis occurred (24 of 36, three of 36, and one of 36, respectively), resulting in reduced VA in 20 eyes (55.5 percent). Complete resolution was achieved in 20 of 25 eyes (80 percent) following dose reduction, spacing, and high-potency topical steroid taper (12 of 25, eight of 25, and 25 of 25, respectively), with VA returning to baseline in 13 of 20 eyes (65 percent).
"As novel promising treatments are incorporated in our anticancer treatment algorithms, postmarket surveillance with real-world studies and close collaboration between ophthalmology and multiple other disciplines of medicine will allow for optimal care for our patients," Vingopoulos said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Exercise Helps Reduce Side Effects From Cancer Treatment
THURSDAY, May 1, 2025 -- Exercise mitigates adverse outcomes associated with cancer and its treatments, according to a review published online April 29 in the British Journal...
Outcomes With Immune Checkpoint Inhibitors Similar for Older, Younger Patients
TUESDAY, April 29, 2025 -- Patients with cancer aged 65 years and older receiving immune checkpoint inhibitors (ICIs) derive similar clinical outcomes as younger patients...
Prevalence of Most Cancer Risk Factors Unchanged Before, After Pandemic
THURSDAY, April 24, 2025 -- Smoking rates continued to decline during the COVID-19 pandemic, but other major risk factors for cancer remained stable, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.